eli lilly tirzepatide cease and desist letter The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide Legal Action by Eli Lilly

Appetite Regulation GLP-1 tells your brain you feel full, helping reduce overeating

We believe in supporting you every step of the waymonitoring your results, adjusting your treatment as needed, and ensuring that you use tirzepatide safely and effectively

Excess supplementation of iron or B12 when you don't need it can cause problems

INDIVIDUAL RESULTS VARY: Outcomes with tirzepatide vary significantly between individuals

A balanced diet rich in vitamins and minerals, particularly magnesium, potassium, and calcium, supports musculoskeletal health

Patients should never extend medication use intentionally to save costs